Form EFFECT Outlook Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BTIG Downgrades Outlook Therapeutics Incs. (OTLK) to Neutral
August 30, 2023 9:22 AM EDTBTIG analyst Julian Harrison downgraded Outlook Therapeutics Incs. (NASDAQ: OTLK) from Buy to Neutral.
The analyst comments "Outlook could disrupt over half the ocular anti-VEGF injection market by volume (>3.5 million injections/yr in the US) with what could emerge as the first FDA-approved intravitreal formulation of bevacizumab. Compounded bevacizumab is currently... More
